iCAD, Inc. will present new studies validating its artificial intelligence (AI) powered ProFound Breast Health Suite for uncovering hidden heart or vascular disease and predicting a woman's risk for developing breast cancer in the next one- or two-years. Researchers will present their findings at the Radiological Society of North America's (RSNA) annual meeting in Chicago, Nov. 27 - 30, 2023. Blending artificial intelligence with computer-aided detection (AI CAD), the iCAD software platform, ProFound Breast Health Suite, can screen a single mammogram for two of the top causes of death for women: breast cancer and heart disease. ProFound AI improves accuracy, streamlines clinical workflow and delivers results to patients more quickly. The calcium deposits appeared more common and widespread with age, as expected. Axel Gräwingholt, M.D., head of mammography screening at Radiologie am Theater in Germany, will present
his team?s findings from a retrospective study of ProFound Risk for 2D Mammography. He and his colleagues
assessed ProFound Risk?s effectiveness in identifying women at high risk for developing breast cancer in the
next two years based on microscopic changes on their exams. The researchers used ProFound Risk to screen the mammograms of 53,453 women who had received normal results two years earlier from their radiologists. The program flagged 42.8% of the women, or 22,878 patients, at a higher risk for breast cancer. ProFound Risk?s prediction proved correct. The average risk for women in the study who developed breast cancer two years after their mammogram was 2.4 times higher than for those who remained cancer-free. The average risk for invasive cancers exceeded that of ductal carcinoma in situ (DCIS), a slow-growing cancer of the milk ducts.